|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007787,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0038454,
umls-concept:C0065055,
umls-concept:C0199176,
umls-concept:C0201950,
umls-concept:C0301630,
umls-concept:C0428466,
umls-concept:C0522510,
umls-concept:C0580822,
umls-concept:C1280500,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1550594
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-11-27
|
|
pubmed:abstractText |
The intention-to-treat analysis of data from the placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found 80 mg atorvastatin per day reduced the risk of stroke and major coronary events in patients with recent stroke or transient ischemic attack. This benefit was present despite only a 78% net difference in adherence to randomized treatment over the course of the trial. In this exploratory analysis, our aim was to evaluate the benefit and risks associated with achieving a >or=50% low-density lipoprotein cholesterol (LDL-C) reduction from baseline.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1524-4628
|
|
pubmed:author |
pubmed-author:AmarencoPierreP,
pubmed-author:CallahanAlfredA3rd,
pubmed-author:GoldsteinLarry BLB,
pubmed-author:HennericiMichaelM,
pubmed-author:RudolphAmy EAE,
pubmed-author:SPARCL Investigators,
pubmed-author:SillesenHenrikH,
pubmed-author:SimunovicLisaL,
pubmed-author:SzarekMichaelM,
pubmed-author:WelchK Michael AKM,
pubmed-author:ZivinJustin AJA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3198-204
|
|
pubmed:meshHeading |
pubmed-meshheading:17962589-Aged,
pubmed-meshheading:17962589-Anticholesteremic Agents,
pubmed-meshheading:17962589-Brain,
pubmed-meshheading:17962589-Cholesterol, LDL,
pubmed-meshheading:17962589-Female,
pubmed-meshheading:17962589-Follow-Up Studies,
pubmed-meshheading:17962589-Humans,
pubmed-meshheading:17962589-Ischemic Attack, Transient,
pubmed-meshheading:17962589-Lipids,
pubmed-meshheading:17962589-Male,
pubmed-meshheading:17962589-Middle Aged,
pubmed-meshheading:17962589-Risk,
pubmed-meshheading:17962589-Stroke,
pubmed-meshheading:17962589-Time Factors,
pubmed-meshheading:17962589-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
|
|
pubmed:affiliation |
Department of Neurology and Stroke Centre, Bichat University Hospital, Denis Diderot University and Medical School, 46, rue Henri Huchard, 75018, Paris, France. amarenco@ccr.jussieu.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
